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The p53 tumour suppressor gene plays an important role in preventing cancer development. This study 
determined if p53 can be induced in osteosarcoma cell lin  upon treatment with Doxycyline. It was 
demonstrated that induction of p53 resulted in the in ibition of the cyclin E/CDK2 complexes by the activa ion 
of p21. This mechanism could potentially therefore represent an important component of the p53 tumor 
suppressor pathway. 
© 2015 International Formulae Group. All rights reserved. 
 




The p53 tumour suppressor gene plays 
an important role in preventing cancer 
development and loss of p53 function, or loss 
of the ability to activate a p53 response, 
appears to be a pre-requisite for malignant 
progression. In both mice and humans, germ 
line mutations in p53 result in a strong 
predisposition to cancer (Lozano and 
Zambetti, 2005). The mechanisms by which 
p53 functions to afford us this protection 
appear to be related to its ability to respond to 
stress and contribute to either the repair 
of stress-induced damage or the inhibition of 
further proliferation of stressed cells. In this 
way, disparate signals that could constitute 
oncogenic danger - such as oxidative stress, 
DNA damage, hypoxia, oncogene activation 
or loss of normal stromal support - all lead to 
the induction of a p53 response (Vousden, 
2002). However, the ultimate response to p53 
can be quite different, ranging from a 
reversible cell cycle arrest to the induction of 
a number of irreversible responses, such as 
cell death or senescence. This dramatic 
distinction in the outcome of p53 activation - 
death or survival - leads to obvious 
questions of how the choice of response is 
regulated and why p53 initiates these different 
responses. To some extent, the life or death of 
the cell is strongly influenced by the presence 
or absence of p53-independent death or 
survival signals that cooperate with the p53-
activated responses. Probably the best 
understood activity of p53 is as a 
transcription factor that has sequence-specific 
DNA-binding activity and the potential to 
induce the expression of a large number of 
genes. Although bioinformatics studies 
suggested that there may be >4000 human 
genes that contain p53-binding sites (Lu, 
2005), direct analysis using various 






ques have more recently placed this number 
between 500 and 1600 genes (Wei et al., 
2006; Cawley et al., 2004) - still a daunting 
proposition. Key to the regulation of p53 
ubiquitylation is MDM2, an ubiquitin ligase 
that is an essential negative regulator of p53 
(Vousden, 2002). The amount of MDM2 
available appears to be critical in determining 
the outcome: mono-ubiquitylation of p53 by 
low levels of MDM2 allows nuclear export, 
whereas higher levels of MDM2 result in 
poly-ubiquitylation and degradation of p53 by 
the proteasome (Li et al., 2003). The ability of 
different polymorphic forms of p53 to bind 
MDM2 and be exported has been linked to the 
efficiency of apoptotic activity (Dumont et al., 
2003), which suggests that the regulation of 
export may help balance cell cycle arrest 
(which appears to be primarily due to 
transcriptional activity of p53) with apoptosis. 
This work was undertaken to determine 
if p53 is induced in SaOs cell line upon 
treatment with doxycycline and also to 
determine if up-regulation of p53 results in the 
activation of p21 and subsequent down-
regulation of cyclinE.  
 
MATERIALS AND METHODS 
Cell treatment 
Cells were seeded in 100 mm dishes 
and grown for 24 hours to reach 20% or 30% 
confluence. Then, Doxycycline was added to 
a final concentration of 800µM. Cell lines 
were maintained in RPMI medium 
supplemented with 10% fetal bovine serum 
and grown to about 90% confluence for 48 
hours, harvested and stored at -20.  
 
RNA extraction and reverse transcription-
PCR  
RNA was extracted with RNeasy 
(Qiagen) with DNase treatment according to 
manufacturer’s instructions. The integrity and 
quality of RNA was checked by agarose gel 
electrophoresis and absorbance reading at 260 
nm. The purity was also determined according 
to standard procedures. RT-PCR was carried 
out with One Step (Qiagen) using gene-
specific primers and programmes.  
 
Preparation of Whole Cell Lysates 
Lysis Buffer 
(NP-40 Lysis): 150 mM NaCl2, 50 mM 
Tris (pH 8.0), 1% NP-40 {containing Protease 
Inhibitor Cocktail (Table 1)}. 
 
Procedure 
Cell pellets were incubated on ice with 
250 µl of lysis buffer for 30mins, vortexing 
after every 5 mins. The solution was spun at 
14,000 rpm for 10mins and the supernatant 
transferred to a fresh tube. The total protein 




Cell lysates were resolved by 12% 
SDS-PAGE and blotted on a polyvinylidene 
difluoride membrane, blocked and incubated 
with appropriate antibodies, then washed with 
PBS-T and incubated with horseradish 
peroxidase-labelled secondary antibody. 
Specific immunoreactive bands were detected 
with enhanced chemoluminiscence (Pierce). 
 
RESULTS 
The results obtained by RT-PCR 
showed up-regulation of p53 upon treatment 
with 800 µM doxyxycline. No p53 expression 
was observed with the untreated control 
(Figure 1). There was no significant difference 
in the expression of β-actin which was used as 
loading control. Western blot analysis also 
revealed that the treated cells showed an up-
regulation of p53 and a corresponding up-
regulation of p21 and subsequent down-
regulation of cyclinE (Figure 2). 
 











Table 1: Protease Inhibitor Cocktail. 
 






1 mg/ml                     add  5 µl/ml 
1 mg/ml                             5 µl/ml 
10 mg/ml                          50 µl/ml 
100 mM                             2 µl/ml 









In this report, it was demonstrated that 
induction of p53 can result in inhibition of the 
cyclin E/CDK2 complexes by activation of 
p21. Cyclins have previously been found to be 
an indirect target of p53. For example, the 
p53-inducible protein PC3 was shown to 
repress cyclin D transcription in NIH 3T3 
cells (Guardavaccaro et al., 2000). Inhibition 
of cyclin E level is consistent with the tumor 
suppressor activity of p53 since both are 
proto-oncogenes. Cyclin E functions in the 
mid-G1 phase of the cell cycle where, in 
conjunction with its cyclin-dependent kinase 
partner CDK2, it acts to inhibit the 
retinoblastoma tumor suppressor (Harbour 
and Dean, 2000). Consistent with this 
proliferative function, cyclins are found to be 
over-expressed in most human breast cancers 
(Weinstat-Saslow et al., 1995).  Our results 
indicate that Doxycycline treatment of SaOs 
cell line induces the expression of p53 leading 
to the activation of p21 and subsequent down-
regulation of cyclinE. This mechanism could 
Figure 1: RT-PCR showing p53 expression in 
SaOs cell line. 
Figure 2: Western blot analysis. 





potentially therefore represent an important 
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